Haemolytic anaemia, G6PD deficiency, COVID-19, SARS-CoV-2
Hydroxychloroquine has been used worldwide as a first-line treatment for patients hospitalized with COVID-19. Little is known about COVID-19 and its effects on patients with congenital red blood cell disorders. We report a case of haemolytic anaemia in a 32-year-old patient and a fortuitous highlighting of G6PD deficiency. We reviewed the literature to assess the risk of hydroxychloroquine use in this context.
HTML downloads: 206
PDF downloads: 849
Issue: 2020: Vol 7 No 9 (view)